Brand Intelligence Graph
Company Overview
About Trace Neuroscience
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Business Model & Competitive Advantage
UNC13A is among the most genetically validated targets in ALS: genome-wide association studies across tens of thousands of patients have identified UNC13A variants as the primary genetic risk modifier determining ALS disease progression rate. The ASO's mechanism — correcting splicing of UNC13A mRNA to restore normal protein function — addresses a genetic pathway affecting approximately 97% of ALS patients, versus existing approved therapies that target only the ~5% of patients with specific familial mutations.
Competitive Landscape 2025–2026
The direct patient enrollment (skipping healthy volunteer phase) is clinically significant: ALS is a rapidly fatal disease where patients cannot afford the 6-12 month timeline that healthy volunteer trials add to clinical development. Regulators support accelerated timelines for unmet-need conditions, and Trace's direct enrollment signals both regulator concurrence and strong IND safety data.
Key Differentiators
Emerging Innovator
Trace Neuroscience is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Trace Neuroscience with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Trace Neuroscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Trace Neuroscience Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Trace Neuroscience vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →